Hawai‘i Health Equity Research and Outreach Network (HAWAI‘I HERON)

夏威夷健康公平研究和推广网络 (HAWAI–I HERON)

• 批准号: 10821224
• 负责人: TODD B SETO
• 金额: $ 49.95万
• 依托单位: QUEEN'S MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10821224
• 关键词: Hawai; Health; Equity; Research; Outreach

Project Summary It is striking and disheartening that Asian Americans, Native Hawaiians, and other Pacific Islanders (AA-NHPI) experience health disparities that are substantial, growing, and poorly understood. Our project entitled “Hawai‘i Health Equity Research and Outreach Network (HAWAI‘I HERON)” will create an Administrative Core to allow us to quickly respond and participate in multi-institutional studies that support three health equity pillars: equity of voices, equitable data efforts, and equity in clinical trials. First, we will enhance equity of voices by 1) amplifying the voices of our AA-NHPI stakeholder communities; 2) understanding diverse patient perspectives, preferences, and unmet needs; and 3) supporting expansion of culturally and linguistically tailored health education. Second, we will support equitable data efforts by expanding capacity to evaluate outcomes by 1) race/ethnicity; 2) geography; and 3) other social determinants of health. Third, we will promote equity in clinical trials by 1) identifying barriers; 2) employing innovative strategies to increase clinical trial enrollment for AA-NHPI; 3) understanding the impact of the evolving multicultural landscape on trial participation; and 4) increasing training for diverse students and investigators. The HAWAI‘I HERON Administrative Core will foster collaboration with the Food and Drug Administration Office of Minority Health and Health Equity and other institutions that are part of the Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH) network. In addition, we will leverage the Administrative Core to conduct a pilot study involving a discrete choice experiment examining AA- NHPI perceptions and preferences for diabetes medications. We will gain an understanding of AA-NHPI preferences regarding attributes of diabetes medications through administering patient preference surveys to 50 AA and 50 NHPI with type 2 diabetes. Random utility theory will serve as the basis for analysis. This assumes that individuals make choices to maximize their utility (or wellbeing), which they derive from different choices. Mixed logit regression, which allows for heterogeneity in preferences across individuals, will be used to estimate the random utility models. Results will enable us to better understand the importance of different attributes and levels, as well as willingness to trade-off between attributes. We will compare findings for AA to those of NHPI and describe similarities and differences. Sensitivity analysis will be used to test the robustness of the results to different assumptions and model specifications. We will hire and train a Health Equity Fellow to support the discrete choice experiment in diabetes medications and build expertise and scholarship for future work and engagement. Achievement of these aims will enable HAWAI‘I HERON to be an active partner to the FDA Office of Minority Health and Health Equity in collaborative research efforts to advance minority health and health equity focused research, to improve outreach and communications, and to support training and mentoring of diverse students and junior researchers.

项目摘要 令人震惊和沮丧的是，亚裔美国人，夏威夷土著人和其他太平洋岛民（AA-NHPI） 经历着巨大的、不断增长的和人们知之甚少的健康差距。我们的项目名为“夏威夷 健康公平研究和外展网络（HAWAI 'I HERON）”将建立一个行政核心， 我们将迅速作出反应，并参与支持三个卫生公平支柱的多机构研究：公平 声音，公平的数据工作，以及临床试验的公平性。首先，我们将通过以下方式增强声音的公平性：1）放大 我们AA-NHPI利益相关者社区的声音; 2）了解不同的患者观点，偏好， 以及未满足的需求;以及3）支持扩大根据文化和语言定制的健康教育。第二、 我们将通过扩大按1）种族/民族评估结果的能力，支持公平的数据工作; 2） 地理;（3）健康的其他社会决定因素。第三，我们将通过以下措施促进临床试验的公平性： 识别障碍; 2）采用创新策略增加AA-NHPI的临床试验入组人数; 3） 了解不断变化的多元文化环境对审判参与的影响;以及4）增加培训 适合不同的学生和研究人员。HAWAI 'I HERON行政核心将促进与 食品和药物管理局少数民族健康和健康公平办公室以及其他机构， 种族和少数民族健康公平加速联盟（REACH）。此外，我们将 利用行政核心进行试点研究，涉及一个独立的选择实验检查AA- NHPI对糖尿病药物的看法和偏好。我们将了解AA-NHPI 通过对50名患者进行患者偏好调查， AA和50例2型糖尿病NHPI。随机效用理论将作为分析的基础。这假设 个人做出选择以最大化他们的效用（或福祉），他们从不同的选择中获得。 混合logit回归允许个体偏好的异质性，将用于估计 随机效用模型。结果将使我们能够更好地了解不同属性的重要性， 水平，以及愿意在属性之间进行权衡。我们将比较AA和NHPI的结果 并描述相似和不同之处。敏感性分析将用于测试结果的稳健性， 不同的假设和模型规格。我们将雇用和培训一名健康公平研究员， 糖尿病药物的离散选择实验，为未来的工作建立专业知识和奖学金， 订婚这些目标的实现将使夏威夷HERON成为FDA办公室的积极合作伙伴 少数民族健康和健康公平的合作研究工作，以促进少数民族健康和健康公平 重点研究，以改善外联和沟通，并支持培训和指导不同的 学生和初级研究人员。